Skip to content
DataLookout
Menu

NCT05478720

DON in Pediatric Cerebral Malaria

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved at least 1 year 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 9 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Dec 2026 to Nov 30, 2028 Show 4 more changesShow less
    • Eligibility criteria expanded, about 40 words
    • Secondary endpoints: details revised at 1 of 8 entries
    • Study description revised
    • Publications: details revised at 2 of 2 entries
  2. Notable Primary and study completion dates: Dec 2025 to Dec 2026v9 Show 4 more changesShow less
    • Eligibility criteria shortened, about 17 words
    • Primary endpoints: 3 to 4
    • Publications: details revised at 1 of 2 entries
    • Study description expanded, about 2 words
  3. Minor Study description shortened, about 7 wordsv8
  4. Notable Eligibility criteria expanded, about 31 words
    • Site details revised at 2 of 2 sites
    • Study description shortened, about 2 words
    v7
  5. Minor Enrollment target: 150 to 152
    • Interventions: 6-diazo-5-oxo-L-norleucine (DON) (Drug), Placebo (Drug) to 6-diazo-5-oxo-L-norleucine (DON) (Drug), 6-diazo-5-oxo-L-norleucine (DON) (Drug), Placebo (Drug)
    • Study description expanded, about 369 words
    v6
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Enrollment target: 80 to 150v4 Show 7 more changesShow less
    • Primary and study completion dates: Dec 2023 to Dec 2025
    • Eligibility criteria expanded, about 153 words
    • Primary endpoints: 2 to 3
    • Study sites: 1 to 2
    • Interventions: 6-diazo-5-oxo-L-norleucine (DON) (Drug) to 6-diazo-5-oxo-L-norleucine (DON) (Drug), Placebo (Drug)
    • Study arms: 8 to 13
    • Study title shortened, about 3 words
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jul 2022 to Aug 16, 2022
    v3
  3. Minor Study title shortened, about 6 wordsv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of local AEs occurring within 14 days after the administration of DON
Timeframe: 14 days
Incidence of systemic AEs occurring within 14 days after the administration of DON
Timeframe: 14 days
Incidence of systemic SAEs occurring within 14 days after the administration of DON
Timeframe: 14 days
Assessment of Blantyre Coma Score
Timeframe: 14 days

Secondary (8)

PK measurement of DON in sera of recipients measured by half life
PK measurement of DON in sera of recipients measured by volume of distribution
PK measurement of DON in sera of recipients measure by maximum concentration (Cmax)
PK measurement of DON in sera of recipients measure by time of maximal concentration (Tmax)
PK measurement of DON in sera of recipients measure by area under the concentrations vs. time curve (AUC)
Show 3 moreShow less
PK measurement of DON in sera of recipients measure by clearance
PK measurement of DON in sera of recipients measure by elimination rate
PK measurement of DON in sera of recipients measure by terminal T1/2

Arms and interventions

Dose escalation in healthy Malawian adults - 0.1 mg/kg IV DONExperimental

The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.

Dose escalation in healthy Malawian adults - 1.0 mg/kg IV DONExperimental

The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.

Dose escalation in healthy Malawian adults - 5.0 mg/kg IV DONExperimental

The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.

Dose escalation in healthy Malawian adults - 10.0 mg/kg IV DONExperimental

The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.

Dose escalation in Malawian adults with uncomplicated malaria - 0.1 mg/kg IV DONExperimental

The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.

Dose escalation in Malawian adults with uncomplicated malaria - 1.0 mg/kg IV DONExperimental

The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.

Dose escalation in Malawian adults with uncomplicated malaria - 5.0 mg/kg IV DONExperimental

The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.

Dose escalation in Malawian adults with uncomplicated malaria - 10.0 mg/kg IV DONExperimental

The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.

Dose escalation in Malawian children with cerebral malaria - 0.1 mg/kg IV DON - Cohort 1Experimental

After adult doses are shown to be safe. Of the first 6 children with cerebral malaria enrolled, 4 will receive 0.1 mg/kg IV DON, and 2 will receive placebo.

Dose escalation in Malawian children with cerebral malaria - 0.1 mg/kg IV DON - Cohort 2Experimental

10 participants will receive 0.1 mg/kg IV DON, and 2 will receive placebo.

Dose escalation in Malawian children with cerebral malaria - 1.0 mg/kg IV DON - Cohort 3Experimental

14 participants will receive 1.0 mg/kg IV DON, and 4 will receive placebo.

Dose escalation in Malawian children with cerebral malaria - 0.1 or 1.0 mg/kg IV DON - Cohort 4Experimental

36 participants will receive 0.1 mg/kg IV DON (n=12) or 1.0 mg/kg IV DON (n=12), and 12 will receive placebo.

Dose escalation in Malawian children with cerebral malaria - placeboPlacebo comparator

Cohort 1 will dose 2 participants to receive placebo Cohort 2 will dose 2 participants to receive placebo Cohort 3 will dose 4 participants to receive placebo Cohort 4 will dose 12 participants to receive placebo

Drugs: 6-diazo-5-oxo-L-norleucine (DON), Placebo

Sites

2 sites in 1 country